AstraZeneca’s Farxiga succeeds in phase 3 cardiovascular outcomes trial
Farxiga was assessed in a trial, dubbed DECLARE-TIMI 58, in more than 17,000 T2D adult patients having multiple CV risk factors or established CV condition. In the five-year
Farxiga was assessed in a trial, dubbed DECLARE-TIMI 58, in more than 17,000 T2D adult patients having multiple CV risk factors or established CV condition. In the five-year
Symbiosis recently hosted a successful inspection by the FDA for the aseptic manufacture of viral vector products for commercial supply into the U.S market at its GMP manufacturing
The expanded indication for the once-daily single inhaler triple therapy would enable use by patients not adequately treated by a long-acting muscarinic receptor antagonist (LAMA) and long-acting β2-agonist
THRUCOOL offers dedicated cold chain services to safeguard the integrity of pharmaceutical and healthcare shipments during air transportation. These include priority uplift and handling, quick ramp transfers at
Grifols is a global healthcare company based in Spain. Biotest US is a healthcare company based in Florida. According to the complaint, which was announced in August 2018,
OBI-3424 is a DNA alkylating cancer therapeutic agent that targets aldo-keto reductase 1C3 (AKR1C3) overexpressing cancers. AKR1C3 overexpression has been known to be found in various treatment-resistant and
Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand. It is in development in the ready-to-use HypoPal rescue pen for easy, fast and effective
The KUBio biomanufacturing facility for BeiGene will be located in Guangzhou in the Chinese province Guangdong, where other biotech firms are setting up operations, said GE. It will
Bonti is focused on developing fast-acting neurotoxin programs intended to be used in aesthetic and therapeutic applications. According to the acquisition terms, the Irish drug maker will make
AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for